Seeking Alpha
Seeking Alpha Portfolio App for iPad
Finance
(1)
Market Currents

Eli Lilly (LLY) -5.1% after saying it will carry out another Phase III trial of its solanezumab...

  • Wednesday, December 12, 2012, 8:08 AM ET
    Eli Lilly (LLY) -5.1% after saying it will carry out another Phase III trial of its solanezumab treatment in patients with mild symptoms of Alzheimer's disease, and will delay applying for approval in the U.S. and Europe following meetings with regulators. The postponement is unlikely to surprise SA author Brian Wilson, who pointed out that apparent patient improvement in two previous studies was "not statistically significant." (PR)
Track new comments on this story

This news story has 3 comments:

  •  
    a good entry point?
    12 Dec 2012, 08:20 AM Reply Like
  •  
    Don't do it. This stock has nowhere to go but down. This time next year loses their last cash cow (Cymbalta) and the pipeline is garbage at best.
    12 Dec 2012, 08:51 AM Reply Like
  •  
    yeah I was looking at the 10-year chart.... seems ugly. What about their insulin products? Diabetes is pretty much a "growth" story globally. Novo nordisk has been doing quite well on that.

    I guess could just stick with SNY BMY and PFE. BMY has been a dud recently, but SNY and PFE seem to be hanging in there well, especially SNY.
    12 Dec 2012, 09:09 AM Reply Like
LATEST|
TODAY SO FAR|
YESTERDAY
Other date
DJIA (DIA) S&P 500 (SPY)

HEALTHCARE ETFs IN FOCUS

Latest Healthcare Articles
More Latest Articles »